4:55 PM
 | 
Nov 16, 2012
 |  BC Extra  |  Financial News

Dynavax falls after Heplisav panel

Dynavax Technologies Corp. (NASDAQ:DVAX) lost nearly half its market cap on Friday after FDA's Vaccines and Related Biological Products Advisory Committee voted 8-5 with one abstention on Thursday that the company had not gathered enough safety data to support approval of Heplisav,...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >